Oragenics (OGEN) Prices $20M Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
July 1, 2025 8:31 AM EDTSARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Companys Series H Convertible Preferred Stock (Preferred Stock), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Company at an exercise price of $25.00 per share (the Warrants). The combined public Offering price of each share of Preferred Stock together... More
